Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
Travere Therapeutics, Inc. (NASDAQ: TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for people living with rare kidney, liver, and metabolic diseases. The company's key focus is the development of its investigational product candidate, sparsentan. This novel therapy is in late-stage development for treating focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can lead to end-stage kidney disease.
Travere Therapeutics has made significant strides in its mission, marked by several recent achievements. The company reported positive topline data from the pivotal phase-III PROTECT study of sparsentan in IgAN, showing a substantial reduction in proteinuria and potential long-term benefits in preserving kidney function. This led to the conditional marketing authorization of sparsentan under the brand name FILSPARI® in Europe and anticipated full approval in the U.S.
Additionally, Travere Therapeutics is advancing other innovative therapies. The company is exploring the potential of pegtibatinase as the first disease-modifying treatment for classical homocystinuria (HCU), with topline data expected in 2026.
Travere's strategic partnerships, such as with CSL Vifor, amplify its reach and impact. CSL Vifor has exclusive commercialization rights for sparsentan in Europe, Australia, and New Zealand. Together, these companies are dedicated to bringing promising treatments to patients worldwide.
The company's financial condition remains robust, supported by a strong pipeline and successful trials. Travere's commitment to the rare disease community is evidenced by its relentless pursuit of better treatment options and its collaborative efforts with patients, families, and caregivers.
Travere Therapeutics (NASDAQ: TVTX) announced that on September 10, 2024, its Compensation Committee granted inducement equity grants to six new employees. These grants consist of restricted stock units (RSUs) covering a total of 33,500 shares of common stock. The RSUs were granted outside of Travere's 2018 Equity Incentive Plan but are subject to its terms. They were provided as inducements for new employees joining Travere, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs have a four-year vesting schedule, with 25% of the shares vesting annually on the grant date anniversary, contingent on the employee's continued service with Travere.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's management will present on Tuesday, September 17, 2024, at 9:45 a.m. ET. This event provides an opportunity for investors and interested parties to gain insights into Travere's latest developments and strategies.
A live webcast of the presentation will be available on the Investor page of Travere's website at ir.travere.com/events-presentations. For those unable to attend the live event, a replay will be accessible for up to 30 days following the conference. This allows stakeholders to stay informed about Travere's progress and future plans in the healthcare sector.
Ligand Pharmaceuticals (Nasdaq: LGND) announced that its partner Travere Therapeutics received full FDA approval for FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. This approval is based on positive long-term results from the PROTECT Study, showing FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
Key points:
- FILSPARI is the only non-immunosuppressive treatment for IgAN
- Ligand is entitled to a 9% royalty on worldwide net sales of FILSPARI
- FILSPARI demonstrated superior long-term kidney function preservation compared to irbesartan
- The FDA-approved label includes two-year efficacy data
Ligand's CEO, Todd Davis, expressed optimism about FILSPARI's potential as a significant revenue driver for the company in the coming years.
Travere Therapeutics announced FDA full approval of FILSPARI® (sparsentan) to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. FILSPARI is the only non-immunosuppressive treatment that significantly slows kidney function decline in IgAN. The approval is based on positive long-term results from the PROTECT Study, showing superior kidney function preservation compared to irbesartan over two years.
Key points:
- FILSPARI is an oral, once-daily medication that targets glomerular injury in the kidney
- It demonstrated a statistically significant treatment effect of 1.2 mL/min/1.73 m2/year in eGFR slope
- The drug showed durable benefits on proteinuria and was well-tolerated
- FILSPARI has the potential to become foundational care in IgAN
Travere Therapeutics (Nasdaq: TVTX) will present two posters on classical homocystinuria (HCU) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) annual symposium in Porto, Portugal, September 3-6, 2024. The presentations will focus on the trial designs of:
- The pivotal Phase 3 HARMONY Study
- ENSEMBLE long-term extension study
- Cohort 7 in the Phase 1/2 COMPOSE Study
All studies involve pegtibatinase, a novel investigational enzyme replacement therapy for HCU. Travere believes pegtibatinase could become the first disease-modifying therapy for classical HCU by effectively replacing the deficient CBS enzyme activity. The posters will be presented on September 4, 2024, from 6:15 – 8:15 p.m. GMT+1 at the Rosa Mota Pavilion.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two upcoming investor conferences in August 2024. The company will present at the 2024 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, at 2:30 p.m. ET, and the Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, at 12:30 p.m. ET.
A live webcast of the Canaccord Genuity conference presentation will be available on Travere's website investor page, with a replay accessible for up to 30 days after the event. This announcement highlights Travere's commitment to engaging with investors and sharing company updates through these important industry events.
Travere Therapeutics (NASDAQ: TVTX) reported strong Q2 2024 financial results, highlighting the success of FILSPARI® (sparsentan) in treating IgAN. Key points include:
- 521 new patient start forms (PSFs) for FILSPARI, totaling 2,484 since launch
- FILSPARI net product sales of $27.1 million, up 37% from previous quarter
- Total revenue of $54.1 million, including $52.2 million in net product sales
- Cash position of $325.4 million as of June 30, 2024
The company is preparing for the September 5, 2024 PDUFA date for full approval of FILSPARI in IgAN. Travere is also advancing global expansion efforts and progressing its pegtibatinase Phase 3 program for classical homocystinuria.
Travere Therapeutics (NASDAQ: TVTX) has announced that it will release its second quarter 2024 financial results on Thursday, August 1, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update. Investors can access the webcast and dial-in information on Travere's website at ir.travere.com/events-presentations. An archived version of the call will be available for 30 days on the company's website following the live webcast.
Travere Therapeutics (NASDAQ: TVTX) will present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference on July 15, 2024, at 11:30 a.m. ET. The presentation will be accessible via live webcast on the company's Investor page, and a replay will be available for 30 days post-event. The company's management will discuss key developments and insights related to their kidney disease therapeutics pipeline.
Travere Therapeutics (NASDAQ: TVTX) announced on June 11, 2024, that its Compensation Committee granted inducement equity grants to three new employees on June 10, 2024. These grants, consisting of 10,500 inducement restricted stock units (RSUs), are part of the company's efforts to attract new talent. The RSUs are governed by the terms of Travere's 2018 Equity Incentive Plan but were granted outside of this plan as inducements material to the new hires. The RSUs will vest over four years, with 25% vesting each year, contingent upon the employees' continued service with the company.
FAQ
What is the current stock price of Travere Therapeutics (TVTX)?
What is the market cap of Travere Therapeutics (TVTX)?
What is the primary focus of Travere Therapeutics?
What is sparsentan?
What recent achievements has Travere Therapeutics made?
What are the indications for FILSPARI®?
Who are Travere Therapeutics' strategic partners?
What is the potential significance of pegtibatinase?
What are the key safety considerations for FILSPARI® therapy?
What is the financial condition of Travere Therapeutics?
How does Travere Therapeutics develop its therapies?
Where can more information about Travere Therapeutics be found?
